Details
Stereochemistry | ACHIRAL |
Molecular Formula | C20H16ClN5O3.CH4O3S |
Molecular Weight | 505.931 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(O)(=O)=O.CNC(=O)C1=NC=CC(COC2=NN=C(NC3=CC=C(Cl)C=C3)C4=C2OC=C4)=C1
InChI
InChIKey=LCMLACPWPXITHP-UHFFFAOYSA-N
InChI=1S/C20H16ClN5O3.CH4O3S/c1-22-19(27)16-10-12(6-8-23-16)11-29-20-17-15(7-9-28-17)18(25-26-20)24-14-4-2-13(21)3-5-14;1-5(2,3)4/h2-10H,11H2,1H3,(H,22,27)(H,24,25);1H3,(H,2,3,4)
Molecular Formula | C20H16ClN5O3 |
Molecular Weight | 409.826 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Molecular Formula | CH4O3S |
Molecular Weight | 96.106 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
Telatinib (Bay-579352) developed by Bayer is an orally available and highly potent inhibitor of tyrosine kinases VEGFR2,VEGFR3, PDGFR and c-Kit. Telatinib is a potent inhibitor of angiogenesis. Telatinib caused a significant decrease in endothelium-dependent and endothelium-independent vasodilation. Telatinib demonstrates anti-tumor activity in various cancer models. Telatinib is ready for phase III clinical trials for the treatment of gastric cancer. In 2010, it has been granted orphan drug status by the FDA. Most frequent adverse events were pain, nausea, voice changes and fatigue.
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL279 |
6.0 nM [IC50] | ||
Target ID: CHEMBL1955 |
4.0 nM [IC50] | ||
Target ID: P26618 Gene ID: 18595.0 Gene Symbol: Pdgfra Target Organism: Mus musculus (Mouse) |
15.0 nM [IC50] | ||
Target ID: CHEMBL1936 |
1.0 nM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
|||
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Gateways to clinical trials. | 2007 Jan-Feb |
|
Phase I dose escalation study of telatinib (BAY 57-9352) in patients with advanced solid tumours. | 2008 Nov 18 |
|
Phase I evaluation of telatinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in combination with irinotecan and capecitabine in patients with advanced solid tumors. | 2010 Apr 1 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/21378200
twice-daily continuously, 450-900 mg
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/19636022
Telatinib inhibits VEGF-dependent proliferation of human umbilical vein endothelial cells (HUVECs) with an IC50 of 26 nM and PDGF-stimulated growth of human aortic smooth muscle cells with an IC50 of 249 nM.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Dec 15 16:26:27 GMT 2023
by
admin
on
Fri Dec 15 16:26:27 GMT 2023
|
Record UNII |
571LVA9UMS
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Systematic Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
NCI_THESAURUS |
C1742
Created by
admin on Fri Dec 15 16:26:27 GMT 2023 , Edited by admin on Fri Dec 15 16:26:27 GMT 2023
|
||
|
NCI_THESAURUS |
C129825
Created by
admin on Fri Dec 15 16:26:27 GMT 2023 , Edited by admin on Fri Dec 15 16:26:27 GMT 2023
|
||
|
NCI_THESAURUS |
C1967
Created by
admin on Fri Dec 15 16:26:27 GMT 2023 , Edited by admin on Fri Dec 15 16:26:27 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
571LVA9UMS
Created by
admin on Fri Dec 15 16:26:27 GMT 2023 , Edited by admin on Fri Dec 15 16:26:27 GMT 2023
|
PRIMARY | |||
|
C87837
Created by
admin on Fri Dec 15 16:26:27 GMT 2023 , Edited by admin on Fri Dec 15 16:26:27 GMT 2023
|
PRIMARY | |||
|
332013-26-0
Created by
admin on Fri Dec 15 16:26:27 GMT 2023 , Edited by admin on Fri Dec 15 16:26:27 GMT 2023
|
PRIMARY | |||
|
9870815
Created by
admin on Fri Dec 15 16:26:27 GMT 2023 , Edited by admin on Fri Dec 15 16:26:27 GMT 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |